JHS Sven.Lab.

Why is JHS Svendgaard Laboratories Ltd falling/rising?

As of 31-Aug, JHS Svendgaard Laboratories Ltd's stock price is at 8.16, reflecting a 2.39% decline. The stock has significantly underperformed, with a year-to-date drop of 17.24% and a long-term decline of 61.01% over three years, indicating a bearish trend despite some recent positive investor activity.

As of 31-Aug, JHS Svendgaard Laboratories Ltd's stock price is falling, currently at 8.16, which reflects a decrease of 0.2 or 2.39%. The stock has been underperforming significantly, with a consecutive decline over the last five days, resulting in a total drop of 10.95% during this period. Additionally, the stock has shown poor performance compared to the benchmark Sensex, with a 1-week decline of 10.62% against the Sensex's minor drop of 0.53%.<BR><BR>Year-to-date, the stock has decreased by 17.24%, which is notably worse than the Sensex's decline of 9.70%. Over the past year, the stock has fallen by 24.51%, while the Sensex has only decreased by 3.57%. The long-term performance is also concerning, with a staggering 61.01% decline over three years compared to the Sensex's gain of 18.70%, and a 62.10% drop over five years against a 33.72% increase in the benchmark.<BR><BR>Despite some positive signs, such as rising investor participation with a delivery volume increase of 106.27% on August 28, the overall trend indicates a lack of momentum for the stock. It is currently trading higher than its 50-day moving average but lower than its 5-day, 20-day, 100-day, and 200-day moving averages, suggesting a bearish trend. Overall, these factors contribute to the stock's current downward trajectory.

Who are in the management team of JHS Sven.Lab.?

The management team of JHS Sven.Lab includes Nikhil Nanda (Managing Director), Rajagopal Chakravarthi (Chairman & Independent Director), and several Independent Directors: Mukul Pathak, Rohina Sanjay Sangtani, Kapil Minocha, and Sunil Arora, along with Additional Directors Vinay Mittal and Upma Chawdhry, and Komal as Company Secretary & Compliance Officer.

The management team of JHS Sven.Lab. includes the following members:<BR><BR>1. Nikhil Nanda - Managing Director<BR>2. Mukul Pathak - Independent Director<BR>3. Rohina Sanjay Sangtani - Independent Director<BR>4. Rajagopal Chakravarthi - Chairman & Independent Director<BR>5. Kapil Minocha - Independent Director<BR>6. Sunil Arora - Additional Independent Director<BR>7. Vinay Mittal - Additional Director<BR>8. Komal - Company Secretary & Compliance Officer<BR>9. Upma Chawdhry - Additional Director<BR><BR>If you need more details about any specific member or their roles, feel free to ask!

What does JHS Sven.Lab. do?

JHS Svendgaard Laboratories Ltd is a micro-cap company that manufactures a range of oral care products within the FMCG industry, reporting net sales of 30 Cr and a net profit of 1 Cr for June 2026. The company has a market cap of INR 72 Cr and operates with a negative return on equity of -1.10%.

Overview:<BR>JHS Svendgaard Laboratories Ltd manufactures a comprehensive range of oral care products and operates within the FMCG industry, categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in an unspecified year and has not reported any status changes. The latest quarterly results indicate net sales and profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 30 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 72 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 44<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.02<BR>- Return on Equity: -1.10%<BR>- Price to Book: 0.42<BR><BR>Contact Details:<BR>- Address: Trilokpur Road Kheri(Kala Amb), Tehsil Nahan District Sirmour Himachal Pradesh : 173030<BR>- Tel: 91-9218-400346<BR>- Email: cs@svendgaard.com<BR>- Website: http://www.svendgaard.com

Who are the peers of the JHS Sven.Lab.?

JHS Sven.Lab.'s peers include Palash Securi., Terai Tea Co, Shri Vasuprada, Simran Farms, Yuvraaj Hygiene, Kovil. Lak. Rol., IEL, Team24 Consumer, and Nakoda Group. JHS Sven.Lab. has average management risk, a below-average capital structure, and a 1-year return of -24.51%, better than Yuvraaj Hygiene but worse than Terai Tea Co's 17.79%.

Peers: The peers of JHS Sven.Lab. are Palash Securi., Terai Tea Co, Shri Vasuprada, Simran Farms, Yuvraaj Hygiene, Kovil. Lak. Rol., IEL, Team24 Consumer, Nakoda Group.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kovil. Lak. Rol. and IEL, while Average management risk is found at JHS Sven.Lab., Simran Farms, and Yuvraaj Hygiene. Below Average management risk is noted for Palash Securi., Terai Tea Co, Shri Vasuprada, Team24 Consumer, and Nakoda Group. Growth is Good at Yuvraaj Hygiene, Average at JHS Sven.Lab. and Simran Farms, and Below Average at Palash Securi., Terai Tea Co, Shri Vasuprada, Kovil. Lak. Rol., IEL, Team24 Consumer, and Nakoda Group. Capital Structure is Excellent at Palash Securi., Average at IEL, and Below Average at JHS Sven.Lab., Terai Tea Co, Shri Vasuprada, Simran Farms, Yuvraaj Hygiene, Kovil. Lak. Rol., Team24 Consumer, and Nakoda Group.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Terai Tea Co at 17.79%, while the lowest is Yuvraaj Hygiene at -51.79%. JHS Sven.Lab.'s 1-year return of -24.51% is better than Yuvraaj Hygiene's but worse than Terai Tea Co's. Additionally, Kovil. Lak. Rol., IEL, and JHS Sven.Lab. have negative six-month returns.

How big is JHS Sven.Lab.?

As of 31st August, JHS Svendgaard Laboratories Ltd has a market capitalization of 72.00 Cr and reported net sales of 108.63 Cr with a net loss of 1.89 Cr over the latest four quarters. Shareholder's funds were 172.73 Cr, and total assets were 197.87 Cr as of March 2025.

As of 31st August, JHS Svendgaard Laboratories Ltd has a market capitalization of 72.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 108.63 Cr. However, it experienced a loss of 1.89 Cr in net profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's funds were recorded at 172.73 Cr, while total assets amounted to 197.87 Cr.

Which are the latest news on JHS Sven.Lab.?

Are JHS Svendgaard Laboratories Ltd latest results good or bad?

The latest results for JHS Svendgaard Laboratories Ltd are concerning, as the company reported a significant revenue increase of 40.52% in Q4 FY26 but also a net loss of ₹3.57 crores, reflecting ongoing operational inefficiencies and raising doubts about its long-term viability.

The latest results for JHS Svendgaard Laboratories Ltd indicate a challenging situation for the company. While the revenue for Q4 FY26 saw a significant increase, reaching ₹32.70 crores—up 40.52% from the previous quarter and 29.92% year-on-year—the company reported a net loss of ₹3.57 crores. This marks a drastic decline of 551.90% compared to the previous quarter, where the company had a modest profit.<BR><BR>Moreover, the operating margin is negative at -4.95%, although it has improved from -21.37% in the same quarter last year. The profit after tax (PAT) margin also remains negative at -10.92%, albeit better than the previous year's -27.65%.<BR><BR>Overall, the results reflect a troubling contradiction: strong revenue growth is not translating into profitability, highlighting ongoing operational inefficiencies. The company has reported losses in five out of the last seven quarters, raising concerns about its long-term viability and ability to generate sustainable returns for shareholders. Given these factors, the latest results can be characterized as bad, indicating significant challenges ahead for JHS Svendgaard.

Should I buy, sell or hold JHS Svendgaard Laboratories Ltd?

When is the next results date for JHS Svendgaard Laboratories Ltd?

The next results date for JHS Svendgaard Laboratories Ltd is 26 May 2026.

The next results date for JHS Svendgaard Laboratories Ltd is scheduled for 26 May 2026.

How has been the historical performance of JHS Sven.Lab.?

JHS Sven.Lab. has faced significant financial challenges, with fluctuating net sales and increasing losses, reporting a profit after tax of -19.74 Cr in March 2025 and negative cash flow from operating activities of -5.00 Cr. Total liabilities matched total assets at 197.87 Cr, indicating a difficult financial position.

Answer:<BR>The historical performance of JHS Sven.Lab. shows a fluctuating trend in net sales and profitability over the years, with significant losses in recent periods.<BR><BR>Breakdown:<BR>JHS Sven.Lab. reported net sales of 92.00 Cr in March 2025, an increase from 70.80 Cr in March 2024, but a decline from 96.21 Cr in March 2023. The total operating income mirrored this trend, reaching 92.00 Cr in March 2025, while total expenditure rose to 96.01 Cr, leading to an operating profit (PBDIT) of -1.13 Cr for the same period. This marked a deterioration from the previous year's operating profit of 3.38 Cr. The company faced a profit before tax of -12.51 Cr in March 2025, worsening from -3.43 Cr in March 2024, and a profit after tax of -19.74 Cr, compared to -4.06 Cr in the prior year. The earnings per share also reflected this decline, showing -2.31 in March 2025. On the balance sheet, total liabilities increased to 197.87 Cr in March 2025, while total assets were reported at 197.87 Cr, indicating a challenging financial position. Cash flow from operating activities was negative at -5.00 Cr, contributing to a net cash outflow of -2.00 Cr for the year. Overall, JHS Sven.Lab. has experienced significant financial challenges, particularly in profitability and cash flow, over the recent years.

Who are the top shareholders of the JHS Sven.Lab.?

The top shareholders of JHS Sven.Lab. include Nikhil Nanda with 30.95%, individual investors with 46.91%, and Vijay Mohan Govila as the highest public shareholder at 2.8%. Additionally, four foreign institutional investors hold a combined 1.6%, while mutual funds hold no shares.

The top shareholders of JHS Sven.Lab. include Nikhil Nanda, who is the promoter with the highest holding at 30.95%. Individual investors collectively hold 46.91% of the shares. Additionally, Vijay Mohan Govila is noted as the highest public shareholder with a stake of 2.8%. The company also has 4 foreign institutional investors (FIIs) holding a combined 1.6% of the shares, while mutual funds do not hold any shares in this company.

Is JHS Sven.Lab. overvalued or undervalued?

As of March 31, 2023, JHS Sven.Lab. is rated as risky and appears undervalued with a PE ratio of -6.59 and a year-to-date return of -37.5%, indicating significant financial distress compared to its peers like Hindustan Unilever and Nestle India.

As of 31 March 2023, the valuation grade for JHS Sven.Lab. moved from does not qualify to risky. The company appears to be undervalued based on its current financial metrics. Key ratios include a PE ratio of -6.59, an EV to EBITDA of -24.39, and a Price to Book Value of 0.64, indicating significant financial distress compared to its peers.<BR><BR>In comparison to its industry peers, JHS Sven.Lab. shows stark contrasts, particularly when compared to Hindustan Unilever with a PE ratio of 53.88 and Nestle India at 75.2, both categorized as very expensive. The company's recent stock performance has been challenging, with a year-to-date return of -37.5%, contrasting sharply with the Sensex's 6.20% gain during the same period. This suggests that while the stock may be undervalued, it faces significant operational challenges that investors should consider.

What is the technical trend for JHS Sven.Lab.?

As of May 30, 2025, JHS Sven.Lab. exhibits a bearish trend with moderate strength, supported by bearish indicators across multiple time frames, despite some mixed signals in momentum.

As of 30 May 2025, the technical trend for JHS Sven.Lab. has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD is bearish, indicating a divergence in momentum. Both the weekly and monthly Bollinger Bands are bearish, reinforcing the downward pressure. Daily moving averages are also bearish, suggesting short-term weakness. The KST shows a mildly bullish signal on the weekly but is bearish on the monthly, while the Dow Theory indicates a mildly bearish trend on the weekly and mildly bullish on the monthly, reflecting mixed signals. Overall, the OBV is mildly bearish on both time frames, contributing to the bearish outlook.

Has JHS Sven.Lab. declared dividend?

Yes, JHS Svendgaard Laboratories Ltd has declared an 8% dividend, amounting to 0.80 per share, with an ex-date of December 26, 2011. However, the company has experienced significant declines in total returns over multiple periods, with the most recent five-year period showing only a slight positive return of 1.1%.

Yes, JHS Svendgaard Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 8%<BR>- Amount per share: 0.80<BR>- Ex-date: 26 Dec 11<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -46.21%, the dividend return was 0%, resulting in a total return of -46.21%.<BR><BR>For the 1-year period, the price return was -36.81%, the dividend return was 0%, leading to a total return of -36.81%.<BR><BR>Over the 2-year period, the price return was -23.29%, the dividend return was 0%, which resulted in a total return of -23.29%.<BR><BR>In the 3-year period, the price return was -48.05%, the dividend return was 0%, culminating in a total return of -48.05%.<BR><BR>During the 4-year period, the price return was -40.37%, the dividend return was 0%, giving a total return of -40.37%.<BR><BR>For the 5-year period, the price return was 1.1%, the dividend return was 0%, resulting in a total return of 1.1%.<BR><BR>Overall, while JHS Svendgaard Laboratories Ltd declared a dividend in the past, the recent total returns indicate significant declines over multiple periods, with the most recent five-year period showing only a slight positive return. The lack of recent dividends suggests a challenging financial environment for the company.